New drugs are found to starve melanoma cells

Oregon ranks 15th in the U.Sin terms of per capita diagnosis, with 27 people suffering from melanoma per 100000 Oregon residentsMen are more likely to develop melanoma than women; mortality rates vary by race and ethnicity, with the highest among whitessource: Wikipedia CC BY-SA 3OSU School of medicine associate professor, OHSU Knight Cancer Research Institute member, Linus CC research fellow Arup Indra, pointed out that melanoma is the fifth most common cancer in the country, and the incidence rate is risingIt's one of the most aggressive cancers, and it kills by metastasizing or spreading to other organs such as the liver, lungs, and brain< br / > Indra's team and collaborators are in the dermatology department of Oregon and OHSU looking for ways to rapidly develop resistance against metastatic melanoma cells< br / > he said: "breakthroughs in understanding the molecular basis of the disease have led to two different drugs, vemurafenib and dabrafenib, which cause clinical reactions in patients with metastatic melanoma with specific gene mutations"But the effectiveness of the drug is limited by high tolerance, which inevitably leads to relapse after 6 to 8 monthsAt present, the 5-year survival rate of stage 4 metastatic melanoma is less than 50%< br / > the researchers guided their efforts to the metabolism of melanoma, the chemical process by which cells surviveThe metabolism of cancer cells is different from that of normal cells< br / > in the high-throughput screening laboratory of OSU, scientists tested nearly 9000 compounds on the melanoma cell line resistant to vemurafenib to determine whether there are drugs that can prevent cell proliferation or induce cell death, some of which are FDA approved drugs< br / > they found that two compounds with similar structures, deguelin and rotenone, are naturally produced pesticides in many plant species that interfere with the metabolism of cancer cellsFurther tests on deguelin showed that it inhibited the oxygen consumption of mitochondria and effectively made cells lack energy< br / > Indra said: "metabolic regulators for metastatic melanoma will be a very attractive treatmentThis drug can be used to treat other cancers, but its role as a metabolic modulator of anti drug metastatic melanoma has not been confirmed "< br / > reference materials: < br / > Evan L carpenter et al, mitochondrial complex I inhibitor deguelin causes metallic reprogramming and sensitises vemurafenib resistant BRAF V600E mutation being metallic landmark cells, molecular cardiogenesis (2019) Doi: 10.1002/mc.23068